InsiderPulseNo transactions found.
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | $2.0M-4.8% | $2.1M+2.6% | $2.1M+0.3% | $2.1M |
| Cost of revenues | $1.5M+5.3% | $1.4M+14.1% | $1.2M-8.0% | $1.3M |
| Research and development | $1.9M-39.4% | $3.1M+59.1% | $2.0M+99.6% | $982K |
| Goodwill and intangibles impairment | $3.6M | — | — | — |
| Selling, general and administrative | $7.0M+62.1% | $4.3M+14.3% | $3.8M-3.6% | $3.9M |
| Total Costs and Expenses | $10.4M-16.7% | $12.4M+78.6% | $7.0M+6.1% | $6.6M |
| Loss from operations | -$8.3M+19.1% | -$10.3M-111.1% | -$4.9M-8.9% | -$4.5M |
| Other income | $111K-42.2% | $192K+1037.5% | $17K | — |
| Loss on extinguishment of debt | -$368K | — | -$554K | — |
| Interest expense | -$23K-5.3% | -$21K+71.8% | -$76K-814.6% | -$8K |
| Total other income (expense) | $88K+144.7% | -$198K+67.8% | -$613K-7300.0% | -$8K |
| Loss before provision for income taxes | -$8.2M+21.5% | -$10.5M-91.1% | -$5.5M-22.3% | -$4.5M |
| Net loss | -$8.2M+21.5% | -$10.5M-91.1% | -$5.5M-22.3% | -$4.5M |
| Preferred shares dividend | -$21.8M | — | — | — |
| Net loss available to common stockholders - basic | -$30.0M-186.6% | -$10.5M | — | — |
| Net loss available to common stockholders - diluted | -$30.0M-186.6% | -$10.5M | — | — |
| Net loss per share attributable to common stockholders- basic (in Dollars per share) | -$2.58-160.6% | -$0.99-43.5% | -$0.69-30.2% | -$0.53 |
| Net loss per share attributable to common stockholders- diluted (in Dollars per share) | -$2.58-160.6% | -$0.99-43.5% | -$0.69 | — |
| Weighted average common shares outstanding - basic (in Shares) | $11.6M+9.7% | $10.6M+33.4% | $8.0M-6.0% | $8.5M |
| Weighted average common shares outstanding - diluted (in Shares) | $11.6M+9.7% | $10.6M+33.4% | $8.0M | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference
Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast
Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
Nutriband AI Kinesiology Tapes approved for Distribution and Sale in Costa Rica